Step therapy for oral methotrexate products (Jylamvo, Xatmep)
Customize your policy alerts
Sign up for simplyhealthcare Policy MTX alerts
Get alerted when Policy MTX changes without checking for updates manually.
Monitor payer policy activity
This policy governs step therapy requirements for specified oral methotrexate products (Jylamvo and Xatmep) for Simply Healthcare Plans members. It defines required prior trial of an initial step drug before coverage of the branded/step-2 products.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Authorization for Jylamvo/Xatmep
Covered when ALL of the following are met
If trial is documented, authorization for Step 2 (Jylamvo or Xatmep) will be covered.
No explicit exclusions for Jylamvo or Xatmep are listed in the policy text. The document specifies the step-therapy sequencing (Step 1: oral methotrexate sodium; Step 2: Jylamvo, Xatmep) but does not identify any product-level or indication-based exclusions for these Step 2 agents.
The policy does not specify any items under a "not medically necessary" section for Jylamvo or Xatmep. Coverage is governed by the step-therapy requirement described (trial of Step 1 drug required) rather than explicit non-coverage language in the provided text.
Products and Codes
| JYLAMVO SOLUTION 2 MG/ML ORAL | Product listed as affected (Jylamvo) |
| XATMEP SOLUTION 2.5 MG/ML ORAL | Product listed as affected (Xatmep) |
| febuxostat 40 mg tablet | Example product listed in adjacent policy text |
| febuxostat 80 mg tablet | Example product listed in adjacent policy text |
Provider Actions / Authorization Requirements
Step therapy prior authorization required
Authorization for Jylamvo or Xatmep requires a prior trial of the Step 1 agent oral methotrexate sodium before coverage will be approved.
- Applies to Jylamvo (methotrexate) and Xatmep (methotrexate).
Coverage conditional on prior Step 1 trial
If the patient has already tried a Step 1 drug (oral methotrexate sodium), authorization for a Step 2 drug (Jylamvo or Xatmep) will be covered.
- Step 1 Drug(s): oral methotrexate sodium.
- Step 2 Drug(s): Jylamvo (methotrexate), Xatmep (methotrexate).
Document prior Step 1 trial
Provider must document a trial of the Step 1 drug (oral methotrexate sodium) as part of the authorization request for Jylamvo or Xatmep.
- Include evidence of trial of oral methotrexate sodium in the prior authorization submission.
Denial risk if prior trial not documented
Failure to document a prior trial of the Step 1 drug (oral methotrexate sodium) may result in denial of authorization for Jylamvo or Xatmep.
- Denial risk applies when trial of the Step 1 agent is not documented.
Background
Methotrexate is used across autoimmune and oncologic indications; within this policy the formulary places oral methotrexate sodium as the Step 1 preferred agent and designates branded oral formulations Jylamvo and Xatmep as Step 2 products. Authorization for the Step 2 agents is contingent on documentation that the member has tried the Step 1 drug.
Definitions
Initial Therapy Requirement
Initial Therapy Requirement
Initial therapy step requirement
Authorization for Step 2 products (Jylamvo, Xatmep) contingent on this trial.
Step Therapy Details
| Step | Required prior therapy | Step 2 products | Coverage |
|---|---|---|---|
| Step 1 | Trial of oral methotrexate sodium documented | N/A (initial preferred agent) | |
| Step 2 | Patient has tried a Step 1 drug (oral methotrexate sodium) | Jylamvo (methotrexate); Xatmep (methotrexate) | Authorization covered when prior trial documented |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.